title: Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
abstract: BACKGROUND
  Proton pump inhibitor-amoxicillin-metronidazole is recommended as second-line Helicobacter pylori therapy in Japan. The authors assessed the efficacy and safety of second-line eradication using the H2-receptor antagonist famotidine as a substitute for proton pump inhibitor.
  
  
  METHODS
  Sixty-one patients who failed in first-line H. pylori eradication using proton pump inhibitor-clarithromycin-amoxicillin were randomly assigned to either second-line therapy including metronidazole: a 7-day course of lansoprazole 30 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d. (lansoprazole group); or a 7-day course of famotidine 40 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d. (famotidine group). Eradication was assessed for each group at least 4 weeks after completing eradication therapy. Drug susceptibility test was performed using 57 strains in pretreatment to clarithromycin, metronidazole, and amoxicillin.
  
  
  RESULTS
  Prior to second-line H. pylori eradication, the rate of resistance to clarithromycin was high at 84% (48/57). Similarly, resistance to metronidazole was low at 5.3% (3/57); however, no amoxicillin-resistant strains were found. The eradication rates for both lansoprazole and famotidine treatment groups were high at 97% (29/30) and 94% (29/31), respectively.
  
  
  CONCLUSIONS
  Famotidine treatment including metronidazole-amoxicillin as second-line therapy provided a high eradication rate similar to lansoprazole therapy. Famotidine is therefore expected to serve as a useful H. pylori eradication regimen in patients with proton pump inhibitor allergy, an economic benefit in terms of reduced health-care costs is also anticipated.
authors.affiliation: Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka Hasama, Oita 879-5593, Japan. murakam@med.oita-u.ac.jp
authors.forename: Kazunari
authors.initials: K
authors.lastname: Murakami
authors.forename: Tadayoshi
authors.initials: T
authors.lastname: Okimoto
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kodama
authors.forename: Ryugo
authors.initials: R
authors.lastname: Sato
authors.forename: Hajime
authors.initials: H
authors.lastname: Miyajima
authors.forename: Masami
authors.initials: M
authors.lastname: Ono
authors.forename: Kunimitsu
authors.initials: K
authors.lastname: Inoue
authors.forename: Koichiro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Satoshi
authors.initials: S
authors.lastname: Otsu
authors.forename: Toshio
authors.initials: T
authors.lastname: Fujioka
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015738:Famotidine / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000378:metabolism; D017211:Treatment Failure
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D064747:Lansoprazole; D008795:Metronidazole; D015738:Famotidine; D000658:Amoxicillin; D017291:Clarithromycin